Centessa Pharmaceuticals plc

Healthcare · Biotechnology · United Kingdom

Last price 40.5 USD (At close: Jun 23, 2026) · Market cap 6.27B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders...